{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:02:29Z","timestamp":1778857349323,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40620-021-00992-5","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T04:04:54Z","timestamp":1613966694000},"page":"653-656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases"],"prefix":"10.1093","volume":"35","author":[{"given":"Julie","family":"Boudali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Haeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Tellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0218-9153","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Prov\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"992_CR1","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836\u20132846","journal-title":"Blood"},{"key":"992_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/17474086.2019.1611423","volume":"12","author":"BS Joly","year":"2019","unstructured":"Joly BS, Coppo P, Veyradier A (2019) An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol 12:383\u2013395","journal-title":"Expert Rev Hematol"},{"key":"992_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/rth2.12160","volume":"3","author":"P Coppo","year":"2019","unstructured":"Coppo P, Cuker A, George JN (2019) Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost 3:26\u201337","journal-title":"Res Pract Thromb Haemost"},{"key":"992_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511\u2013522","journal-title":"N Engl J Med"},{"key":"992_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335\u2013346","journal-title":"N Engl J Med"},{"key":"992_CR6","doi-asserted-by":"publisher","first-page":"e27737","DOI":"10.1002\/pbc.27737","volume":"66","author":"SV Bhoopalan","year":"2019","unstructured":"Bhoopalan SV et al (2019) Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura. Pediatr Blood Cancer 66:e27737","journal-title":"Pediatr Blood Cancer"},{"key":"992_CR7","doi-asserted-by":"publisher","first-page":"e28534","DOI":"10.1002\/pbc.28534","volume":"68","author":"MB Nagel","year":"2021","unstructured":"Nagel MB, Ryder A, Lobbins M, Bhatt N (2021) Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus. Pediatr Blood Cancer 68:e28534","journal-title":"Pediatr Blood Cancer"},{"key":"992_CR8","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00467-019-04281-z","volume":"34","author":"V Kaczmarek","year":"2019","unstructured":"Kaczmarek V et al (2019) Caplacizumab for relapsing thrombotic thrombocytopenic purpura. Pediatr Nephrol Berl Ger 34:1625\u20131628","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"48","key":"992_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.lpm.2019.08.024","volume":"1983","author":"A Picod","year":"2019","unstructured":"Picod A, Prov\u00f4t F, Coppo P (2019) Therapeutic plasma exchange in thrombotic thrombocytopenic purpura. Presse Medicale Paris Fr 1983(48):319\u2013327","journal-title":"Presse Medicale Paris Fr"},{"key":"992_CR10","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1016\/S2352-3026(16)30125-9","volume":"3","author":"BS Joly","year":"2016","unstructured":"Joly BS et al (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e537\u2013e546","journal-title":"Lancet Haematol"},{"key":"992_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.13107","volume":"101","author":"BS Joly","year":"2018","unstructured":"Joly BS, Coppo P, Veyradier A (2018) Pediatric thrombotic thrombocytopenic purpura. Eur J Haematol 101:425\u2013434","journal-title":"Eur J Haematol"},{"key":"992_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008021","author":"P Coppo","year":"2020","unstructured":"Coppo P et al (2020) A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. https:\/\/doi.org\/10.1182\/blood.2020008021","journal-title":"Blood"},{"key":"992_CR13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007599","author":"T Dutt","year":"2020","unstructured":"Dutt T et al (2020) Real-world evidence of caplacizumab use in the management of acute TTP. Blood. https:\/\/doi.org\/10.1182\/blood.2020007599","journal-title":"Blood"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-00992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-021-00992-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-00992-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:59Z","timestamp":1777564559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/2\/653\/8326113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1007\/s40620-021-00992-5","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"22 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PC and FP are members of the Clinical Advisory Board for Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that the parents of the children provided consent for the report of their medical data and that this manuscript was witten under approval of the hospital ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}